Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB.

Liu W, Zhou J, Geng G, Lin R, Wu JH.

Invest New Drugs. 2014 Apr;32(2):227-34. doi: 10.1007/s10637-013-0040-y. Epub 2013 Oct 23.

PMID:
24146017
2.

Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.

Zhou J, Geng G, Wu JH.

Invest New Drugs. 2010 Jun;28(3):291-8. doi: 10.1007/s10637-009-9251-7. Epub 2009 Apr 24.

PMID:
19390783
3.

Syntheses and potential anti-prostate cancer activities of ionone-based chalcones.

Zhou J, Geng G, Batist G, Wu JH.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1183-6. doi: 10.1016/j.bmcl.2008.12.089. Epub 2008 Dec 25.

PMID:
19138519
4.

Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.

Liu B, Geng G, Lin R, Ren C, Wu JH.

Chem Biol Drug Des. 2012 Mar;79(3):300-12. doi: 10.1111/j.1747-0285.2011.01290.x. Epub 2012 Jan 11.

PMID:
22151347
5.

Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.

Yamamoto S, Matsunaga N, Hitaka T, Yamada M, Hara T, Miyazaki J, Santou T, Kusaka M, Yamaoka M, Kanzaki N, Furuya S, Tasaka A, Hamamura K, Ito M.

Bioorg Med Chem. 2012 Jan 1;20(1):422-34. doi: 10.1016/j.bmc.2011.10.067. Epub 2011 Oct 28.

PMID:
22094279
6.

Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.

McCarty MF, Hejazi J, Rastmanesh R.

Integr Cancer Ther. 2014 Sep;13(5):386-95. doi: 10.1177/1534735414534728. Epub 2014 May 26.

PMID:
24867960
7.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ.

Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007.

8.
9.

Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.

Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ.

Oncogene. 2015 Jul;34(28):3700-10. doi: 10.1038/onc.2014.302. Epub 2014 Sep 15.

10.

Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.

Mashima T, Okabe S, Seimiya H.

Mol Pharmacol. 2010 Nov;78(5):846-54. doi: 10.1124/mol.110.064790. Epub 2010 Aug 13.

11.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

12.

NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL.

Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.

13.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

14.

Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.

Helsen C, Marchand A, Chaltin P, Munck S, Voet A, Verstuyf A, Claessens F.

Mol Cancer Ther. 2012 Jun;11(6):1257-68. doi: 10.1158/1535-7163.MCT-11-0763. Epub 2012 Apr 10.

15.

Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.

Han AL, Kumar S, Fok JY, Tyagi AK, Mehta K.

Eur J Cancer. 2014 Jun;50(9):1685-96. doi: 10.1016/j.ejca.2014.02.014. Epub 2014 Mar 20.

PMID:
24656569
16.

20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.

Fousteris MA, Schubert U, Roell D, Roediger J, Bailis N, Nikolaropoulos SS, Baniahmad A, Giannis A.

Bioorg Med Chem. 2010 Oct 1;18(19):6960-9. doi: 10.1016/j.bmc.2010.08.029. Epub 2010 Aug 19.

PMID:
20826091
17.

Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.

Inoue K, Urushibara K, Kanai M, Yura K, Fujii S, Ishigami-Yuasa M, Hashimoto Y, Mori S, Kawachi E, Matsumura M, Hirano T, Kagechika H, Tanatani A.

Eur J Med Chem. 2015 Sep 18;102:310-9. doi: 10.1016/j.ejmech.2015.08.002. Epub 2015 Aug 6.

PMID:
26295173
18.

Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.

Zhou J, Geng G, Shi Q, Sauriol F, Wu JH.

J Med Chem. 2009 Sep 10;52(17):5546-50. doi: 10.1021/jm801218k.

PMID:
19725582
19.

Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.

Martinez-Ariza G, Hulme C.

Pharm Pat Anal. 2015;4(5):387-402. doi: 10.4155/ppa.15.20. Epub 2015 Sep 21. Review.

PMID:
26389532
20.

Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.

Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S.

Cancer Lett. 2012 Mar;316(1):11-22. doi: 10.1016/j.canlet.2011.10.006. Epub 2011 Oct 10.

Items per page

Supplemental Content

Write to the Help Desk